2019) and aged mice (Li et al. 2020). Additionally, the regulatory effects of GSK on osteogenesis were reflected by the up-regulation in mRNA expression of RUNX2, OCN and COL-I in bone of mice with exposure to Dex, which was consistent with the in vitro study showing its stimulatory effect on osteoblastogenesis (Wang et al. 2018). Collectively, this in vivo study discovered the bone-sparing efficacy of GSK in dexamethasone-treated mice and shed light on the potential implications in musculoskeletal disorders arising from the GCs effects. The gene discussed is RUNX2; the disease is musculoskeletal system disorder.